iShares Biotechnology ETF (IBB)
Should You Invest in the iShares Biotechnology ETF (IBB)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund launched on February 5, 2001.
IBB: Beyond The 2025 Surge, Biotech Breakout
iShares Biotechnology ETF is rated a BUY, offering a balanced entry into biotech with large-cap stability and strong recent performance. IBB benefits from catalysts including accelerating M&A and AI-driven R&D efficiencies and more dovish Fed policy, positioning the sector for outperformance in 2026. The fund's market cap-weighted structure emphasizes cash-flow positive giants, better managing idiosyncratic risk compared to equal-weighted biotech peers.
IBB: Biotech's Hot Streak May Cool
iShares Biotechnology ETF (IBB) earns a reiterated hold rating as it consolidates near all-time highs with balanced risk/reward. IBB's valuation is fair at a 19x P/E and low 3% EPS growth, resulting in an unimpressive PEG ratio. Technical momentum has slowed, with potential consolidation around $180 and long-term support near $150.
Here's Why Biotech ETFs Are Rallying Hard
Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.
Mizuho's Jared Holz on what biotech dealmaking looks like in 2026
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the surge in pharma M&A in 2025, ACA subsidies expiring, and more.
2 Top Growth Themes Beyond AI and How to Invest in Them
The AI trade has been wobbling quite a bit in recent weeks, to say the least. And while the popping of the AI bubble hasn't yet happened, it does seem like much of the damage done to particular overheated AI stocks has been a bit overdone.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.
Should You Invest in the iShares Biotechnology ETF (IBB)?
Launched on February 5, 2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.
2 Brilliant Biotech ETFs to Watch in 2026
As the AI trade gets overheated and calls for some sort of bursting of the AI bubble grow louder, it might make sense to look to opportunities to be had within other sectors.
Inside the Recent Strength in Biotech ETFs
Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.
Biotech ETFs Hovering Around a 52-Week: Here's Why
Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied 26.1% over the past six months (as of Oct. 27, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 24.4%). Year to date, IBB has risen 18.2% versus SPY's 17.2% gain.
Biotech ETFs Bounce Back in 2025: Here's Why
Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.
